SCHEMBL17540477

SCHEMBL17540477

C/C=C/C[C@@H](C)C[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 14/20 1.00
FPR1 P21462 2/20 0.85
PPIA P62937 6/20 0.83
ABCC1 P33527 2/20 0.83
ABCC2 Q92887 2/20 0.83
FKBP1B P68106 2/20 0.83
MEN1 O00255 1/20 0.83
NPC1 O15118 1/20 0.83
ABCC3 O15438 1/20 0.83
GMNN O75496 1/20 0.83
USP2 O75604 1/20 0.83
SLCO2B1 O94956 1/20 0.83
ABCB11 O95342 1/20 0.83
LMNA P02545 1/20 0.83
POLB P06746 1/20 0.83
CYP3A4 P08684 1/20 0.83
MAPT P10636 1/20 0.83
RARB P10826 1/20 0.83
CYP2C9 P11712 1/20 0.83
CYP3A5 P20815 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20180085 1.00 ABCB1 (1.00) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL21165779 1.00 ABCB1 (1.00) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL14435531 1.00 ABCB1 (1.00) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL22047168 1.00 ABCB1 (1.00) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL20076121 0.97 ABCB1 (0.94) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL21016042 0.96 ABCB1 (0.92) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL23320225 0.96 ABCB1 (0.92) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL22435569 0.96 ABCB1 (0.91) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL22251734 0.95 ABCB1 (0.91) ABCB1FPR1PPIAABCC1ABCC2
SCHEMBL16063958 0.95 ABCB1 (0.90) ABCB1FPR1PPIAABCC1ABCC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025079025-A1 IDES-RAPAMYCIN CONJUGATE IN AAV GENE THERAPY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-04-17 WO disclosed
EP-3352796-B1 DRUG FORMULATION BASED ON PARTICULATES COMPRISING POLYSACCHARIDE-VITAMIN CONJUGATE U S TIANYOU CAPITAL CORP (US) 2025-03-05 EP disclosed
US-20240426814-A1 PRETREATMENT AGENT IN NON-AGGLUTINATION ASSAYS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2024-12-26 US disclosed
US-12111310-B2 Pretreatment agent in non-agglutination assays SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2024-10-08 US disclosed
CN-112004524-B Drug delivery system 耶路撒冷希伯来大学伊森姆研究发展有限公司 2024-09-10 CN disclosed
US-20240159781-A1 SANDWICH ASSAY FOR SMALL MOLECULES SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2024-05-16 US disclosed
US-11913965-B2 Sandwich assay for small molecules SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2024-02-27 US disclosed
CN-116457657-A Determination method of relative fu ratio based on dynamic analysis 中外制药株式会社 2023-07-18 CN disclosed
US-11592439-B2 Pretreatment agent in non-agglutination assays SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2023-02-28 US disclosed
US-20230041197-A1 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR GLAS USA LLC 2023-02-09 US disclosed
EP-4036572-A1 METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS Siemens Healthcare Diagnostics Inc. (US) 2022-08-03 EP disclosed
US-11377483-B2 Sandwich assay design for small molecules SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2022-07-05 US disclosed
EP-2176658-B1 METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS SIEMENS HEALTHCARE DIAGNOSTICS INC (US) 2022-06-01 EP disclosed
US-20160052972-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION S&T GLOBAL INC. 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052972-A1 NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION HAVCR2, TSLP, ICOS ABCB1 198/4885FPR1 1029/4885PPIA 710/4885
US-11377483-B2 Sandwich assay design for small molecules SHBG, SERPINA6, SPR ABCB1 4290/4885FPR1 4318/4885PPIA 3820/4885
US-20230041197-A1 TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOMODULATOR FABP2, IL2, TSLP ABCB1 2564/4885FPR1 1026/4885PPIA 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.